{"id":"bone-modifying-agent","safety":{"commonSideEffects":[{"rate":null,"effect":"Osteonecrosis of the jaw"},{"rate":null,"effect":"Atypical fractures"},{"rate":null,"effect":"Gastrointestinal upset"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These agents work by targeting the balance between bone resorption and formation. Common mechanisms include inhibition of osteoclast-mediated bone resorption (e.g., bisphosphonates, denosumab) or stimulation of osteoblast-mediated bone formation. By shifting this balance toward bone formation or reducing excessive resorption, they increase bone mineral density and mechanical strength.","oneSentence":"Bone modifying agents alter bone remodeling by inhibiting osteoclast activity or promoting osteoblast function to increase bone density and reduce fracture risk.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:22:14.951Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis prevention and treatment"},{"name":"Bone loss associated with various conditions"}]},"trialDetails":[{"nctId":"NCT06745024","phase":"PHASE3","title":"Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-04-14","conditions":"Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm","enrollment":280},{"nctId":"NCT04549207","phase":"PHASE4","title":"Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2020-10-09","conditions":"Breast Cancer, Castration-resistant Prostate Cancer","enrollment":240},{"nctId":"NCT04506073","phase":"PHASE2","title":"Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2020-11-09","conditions":"Parkinson's Disease","enrollment":45},{"nctId":"NCT01811290","phase":"","title":"A Pilot Study Assessing the Impact of Gilenya Therapy on Bone Density Change in Relapsing Forms of Multiple Sclerosis","status":"UNKNOWN","sponsor":"Simnad, Virginia, M.D.","startDate":"2013-01","conditions":"Multiple Sclerosis","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":80,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zoledronate","Denosumab","Pamidronate"],"phase":"marketed","status":"active","brandName":"Bone modifying agent","genericName":"Bone modifying agent","companyName":"Ottawa Hospital Research Institute","companyId":"ottawa-hospital-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bone modifying agents alter bone remodeling by inhibiting osteoclast activity or promoting osteoblast function to increase bone density and reduce fracture risk. Used for Osteoporosis prevention and treatment, Bone loss associated with various conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}